Defining HYCH: orthostatic intolerance without tachycardia

Standard orthostatic testing has a binary structure: your heart rate rises to POTS threshold, or it doesn't. Your blood pressure falls to orthostatic hypotension threshold, or it doesn't. If neither happens, the test is interpreted as normal and the clinical conclusion is that orthostatic physiology is not driving your symptoms. This binary framework is built on the assumption that the measurements used — heart rate and peripheral blood pressure — are sufficient to capture whether orthostatic intolerance is present. A 2018 paper by Dr. Peter Novak at Brigham and Women's Hospital demonstrates that this assumption is false. Novak defined and documented a distinct subtype of orthostatic intolerance — Hypocapnic Cerebral Hypoperfusion, or HYCH — in patients whose standard tilt tests were completely normal but who were experiencing significant cerebral blood flow reduction through a mechanism that heart rate and blood pressure monitoring cannot detect.

Defining HYCH: The Condition Standard Testing Can't See

HYCH patients present with classic orthostatic intolerance symptoms: dizziness, cognitive difficulty, visual changes, fatigue, and feeling unwell when upright. They have often been through conventional evaluation. Their heart rates during tilt do not cross the 30 bpm POTS threshold. Their blood pressures do not fall to orthostatic hypotension criteria. By the conventional framework, they have been told their orthostatic physiology is normal and their symptoms require explanation elsewhere. Some have been referred to psychiatry. Some have been told their symptoms are functional. The evaluation that produced this conclusion simply was not measuring the variable responsible for their symptoms.

The defining feature of HYCH is cerebral hypoperfusion driven by hypocapnia — falling CO₂ — rather than by the hemodynamic failure that drives POTS or orthostatic hypotension. When HYCH patients stand, they hyperventilate subtly. Their breathing rate increases and they blow off CO₂ faster than it is produced. Arterial CO₂ falls. The brain's cerebrovascular system responds to the falling CO₂ with immediate vasoconstriction — cerebral arterioles constrict, reducing cerebral blood flow velocity. This happens through a direct chemical mechanism, independent of heart rate and blood pressure, and it is entirely invisible to an arm cuff and a pulse oximeter.

What Novak Found When He Measured What Standard Testing Doesn't

Novak's 2018 PLOS ONE paper added two measurements to tilt table testing that standard protocols omit: end-tidal CO₂ monitoring via capnography and middle cerebral artery blood flow velocity via transcranial Doppler. These two additions make visible what standard tilt testing cannot see — the CO₂ environment and the cerebrovascular response to it in real time.

In HYCH patients, the findings were definitive. End-tidal CO₂ during tilt fell to an average of approximately 26 mmHg, compared to approximately 37 mmHg in healthy controls. This is a 11 mmHg difference — well into the range where cerebrovascular reactivity produces substantial blood flow reduction. The cerebrovascular response was exactly what the physiology predicts: middle cerebral artery blood flow velocity fell by approximately 22 percent during tilt. While standard monitoring was showing normal heart rate and normal blood pressure, the brain was receiving substantially less blood than it needed. The arm cuff said everything was fine. The transcranial Doppler said the opposite.

The symptom correlation was consistent with the physiology. Patients reported dizziness, cognitive difficulty, and general unwellness during tilt at the same time as cerebral blood flow velocity was declining. Their symptoms were not fabricated or unexplained. They were the expected neurological outputs of 22 percent cerebral hypoperfusion — the same output that would be expected in anyone whose brain was receiving significantly less blood than baseline.

HYCH and POTS: Same Problem, Different Compensations

One of the most important findings in the Novak HYCH paper is the comparison between HYCH patients and POTS patients during tilt. The two groups had strikingly similar cerebral blood flow reductions during the orthostatic challenge — approximately 22 percent in both groups. The central problem, inadequate cerebral perfusion during upright posture, was the same in magnitude. The difference was in how the peripheral cardiovascular system responded to that problem.

In POTS patients, the compensatory response to orthostatic stress is tachycardia — the heart rate accelerates, sometimes dramatically, in an attempt to maintain cardiac output and cerebral perfusion against the gravitational challenge. The tachycardia crosses the 30 bpm threshold and gets detected. In HYCH patients, this tachycardia compensation is absent or insufficient to reach threshold. POTS and HYCH represent the same underlying cerebral perfusion failure with different peripheral compensation patterns. The condition is detected when the compensation is large enough to trigger a diagnostic threshold. When it isn't — either because the compensation pathway is less active or because the primary mechanism is CO₂-driven vasoconstriction rather than hemodynamic failure — the same degree of cerebral hypoperfusion produces a normal-looking standard tilt test.

This framing matters for how orthostatic intolerance is understood. POTS is not a disease defined by tachycardia. The tachycardia is a marker that the condition exists and has triggered a compensatory response. The condition itself is inadequate cerebral blood flow during upright posture. HYCH patients have the same inadequate cerebral blood flow without the marker. Their absence from the POTS diagnosis is an artifact of diagnostic threshold design, not a finding of different physiology.

The CO₂ Mechanism in Detail

The mechanism by which HYCH produces cerebral hypoperfusion is worth understanding specifically, because it explains both why standard testing misses it and why the treatment implications differ from POTS. CO₂ regulates cerebrovascular tone through a direct chemical effect on smooth muscle in cerebral arteriole walls. When arterial CO₂ is in the normal range (approximately 35-45 mmHg), cerebral arterioles maintain appropriate diameter and blood flow is adequate. When CO₂ falls below normal — hypocapnia — arterioles constrict. The vasoconstriction is proportional to the CO₂ reduction and fast-acting, occurring over seconds to minutes.

Postural hyperventilation is the trigger. In susceptible patients, standing increases respiratory rate above what metabolic demand requires, and the excess ventilation blows off CO₂. This is not dramatic hyperventilation that is visible from across the room. It is a subtle elevation in breathing rate and depth that produces a meaningful CO₂ reduction — enough to drop from 37 mmHg to 26 mmHg, as Novak's HYCH patients showed. The physiological consequences of that CO₂ drop are large. A 10 mmHg reduction in end-tidal CO₂ can reduce cerebral blood flow by 20 to 30 percent through vasoconstriction alone, without any change in blood pressure or heart rate.

This is why CO₂ monitoring and transcranial Doppler together define what the Novak paper found: the missing measurement for a missing diagnosis. Neither alone is sufficient. CO₂ monitoring identifies whether the chemical environment is changing. TCD identifies whether cerebral blood flow is responding to it. Together, they reveal the mechanism that standard tilt testing cannot see.

What a Normal Tilt Result Actually Means

The Novak HYCH paper reframes what a normal tilt table test can and cannot conclude. A normal result — no POTS threshold, no orthostatic hypotension threshold — means the peripheral cardiovascular compensatory responses stayed within their defined limits. It does not mean that cerebral blood flow was maintained. It does not mean that CO₂ was stable. It does not mean orthostatic intolerance is not present. It means the specific proxy measurements used did not detect a threshold crossing. Whether the thing those proxies were trying to proxy — adequate cerebral perfusion — was actually maintained is a separate question that requires different measurements to answer.

For patients who have received a normal tilt result and been told their orthostatic physiology is normal, the Novak data establish a specific basis for questioning that conclusion. The right follow-up is not to accept the normal result as comprehensive. It is to ask whether CO₂ was monitored during the test and whether cerebral blood flow velocity was measured. If neither was monitored — and in standard clinical tilt protocols neither typically is — then the evaluation assessed compensatory peripheral cardiovascular responses and nothing about the cerebrovascular environment in which those responses were operating. Novak's own larger 2024 study at the Brigham autonomic laboratory, with 2,627 patients, confirmed that subjective symptom burden and objective autonomic testing results have essentially zero correlation — meaning the severity of how you feel is not a reliable guide to what measuring the right variables will reveal. HYCH is the mechanistic demonstration of exactly why that correlation fails.